DDR1 inhibition as a new therapeutic strategy for colorectal cancer

Abstract

The clinical management of metastatic colorectal cancer (mCRC) is still a major challenge. Recently, we discovered that nilotinib, an approved treatment for chronic myeloid leukaemia, inhibits invasive and metastatic properties of CRC cells by targeting the kinase activity of receptor for collagens DDR1 (Discoïdin Domain Receptor tyrosine kinase 1), suggesting that nilotinib could be an effective strategy to treat mCRC.

Keywords

• colorectal cancer
• invasion
• metastasis
• ddr1 tyrosine kinase receptor
• collagen
• targeted therapy
• nilotinib